High Expression of CLEC11A Predicts Favorable Prognosis in Acute Myeloid Leukemia
ConclusionCLEC11A may be used as a prognostic biomarker, and could do benefit for AML patients by providing precise treatment indications, and its unique gene pattern should aid in further understanding the heterogeneous AML mechanisms.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Leukemia | Study